WO2023063242A1 - IFN-γへ選択的に結合するオリゴヌクレオチドを含有する自己免疫性疾患治療薬およびそのオリゴヌクレオチド - Google Patents
IFN-γへ選択的に結合するオリゴヌクレオチドを含有する自己免疫性疾患治療薬およびそのオリゴヌクレオチド Download PDFInfo
- Publication number
- WO2023063242A1 WO2023063242A1 PCT/JP2022/037560 JP2022037560W WO2023063242A1 WO 2023063242 A1 WO2023063242 A1 WO 2023063242A1 JP 2022037560 W JP2022037560 W JP 2022037560W WO 2023063242 A1 WO2023063242 A1 WO 2023063242A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- autoimmune
- autoimmune disease
- base
- disease
- dna
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 74
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 53
- 108010074328 Interferon-gamma Proteins 0.000 title claims abstract description 43
- 102100037850 Interferon gamma Human genes 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 15
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 230000027455 binding Effects 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 22
- 208000004631 alopecia areata Diseases 0.000 claims description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 229940126585 therapeutic drug Drugs 0.000 claims description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- 229920000249 biocompatible polymer Polymers 0.000 claims description 9
- 230000001363 autoimmune Effects 0.000 claims description 8
- 230000005784 autoimmunity Effects 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 206010013774 Dry eye Diseases 0.000 claims description 6
- 102000008070 Interferon-gamma Human genes 0.000 claims description 6
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 6
- 206010039705 Scleritis Diseases 0.000 claims description 6
- 229960003130 interferon gamma Drugs 0.000 claims description 6
- 150000002605 large molecules Chemical class 0.000 claims description 6
- 150000003384 small molecules Chemical class 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- -1 small molecule compound Chemical class 0.000 claims description 5
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims description 4
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims description 4
- 208000018359 Systemic autoimmune disease Diseases 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 208000037896 autoimmune cutaneous disease Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000026872 Addison Disease Diseases 0.000 claims description 3
- 208000004300 Atrophic Gastritis Diseases 0.000 claims description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- 206010011796 Cystitis interstitial Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 206010015084 Episcleritis Diseases 0.000 claims description 3
- 208000036495 Gastritis atrophic Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000003782 Raynaud disease Diseases 0.000 claims description 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 3
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 3
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 206010047642 Vitiligo Diseases 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 229920001222 biopolymer Polymers 0.000 claims description 3
- 208000003167 cholangitis Diseases 0.000 claims description 3
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 3
- 229930182912 cyclosporin Natural products 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 208000003532 hypothyroidism Diseases 0.000 claims description 3
- 230000002989 hypothyroidism Effects 0.000 claims description 3
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 3
- 229960000681 leflunomide Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 206010036601 premature menopause Diseases 0.000 claims description 3
- 208000017942 premature ovarian failure 1 Diseases 0.000 claims description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 229960001967 tacrolimus Drugs 0.000 claims description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 3
- 206010043778 thyroiditis Diseases 0.000 claims description 3
- 208000019802 Sexually transmitted disease Diseases 0.000 claims description 2
- 229930105110 Cyclosporin A Natural products 0.000 claims 2
- 206010003549 asthenia Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 abstract description 29
- 238000011109 contamination Methods 0.000 abstract description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 108091008102 DNA aptamers Proteins 0.000 description 44
- 108091023037 Aptamer Proteins 0.000 description 33
- 230000000694 effects Effects 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 102000043129 MHC class I family Human genes 0.000 description 14
- 108091054437 MHC class I family Proteins 0.000 description 14
- 102000043131 MHC class II family Human genes 0.000 description 14
- 108091054438 MHC class II family Proteins 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 210000004209 hair Anatomy 0.000 description 11
- 201000004384 Alopecia Diseases 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 208000024963 hair loss Diseases 0.000 description 8
- 230000003676 hair loss Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 210000003780 hair follicle Anatomy 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 5
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 229960003957 dexamethasone Drugs 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 229960003632 minoxidil Drugs 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000004918 root sheath Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 102000015617 Janus Kinases Human genes 0.000 description 4
- 108010024121 Janus Kinases Proteins 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000006058 immune tolerance Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000010827 pathological analysis Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000004012 Tofacitinib Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000003660 hair regeneration Effects 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 description 1
- WIPHNVWGXOHNEF-UHFFFAOYSA-N 7-thiophen-2-yl-1h-imidazo[4,5-b]pyridine Chemical compound C1=CSC(C=2C=3N=CNC=3N=CC=2)=C1 WIPHNVWGXOHNEF-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100246038 Mus musculus Ptpn5 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- DREIJXJRTLTGJC-ZLBJMMTISA-N chembl3137308 Chemical compound C([C@H]1C[C@@](O)(C2)C3)C2C[C@H]3[C@H]1NC1=C2C=CNC2=NC=C1C(=O)N DREIJXJRTLTGJC-ZLBJMMTISA-N 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229950004645 emapalumab Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical class 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006057 immunotolerant effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229950005157 peficitinib Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- SYIKUFDOYJFGBQ-YLAFAASESA-N tofacitinib citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 SYIKUFDOYJFGBQ-YLAFAASESA-N 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229950000088 upadacitinib Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940039916 xeljanz Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
Definitions
- the present invention relates to an autoimmune disease therapeutic drug containing an oligonucleotide that selectively binds to interferon- ⁇ (IFN- ⁇ ) and the oligonucleotide.
- IFN- ⁇ interferon- ⁇
- Alopecia areata is a hair loss symptom that occurs widely, regardless of age or gender, and frequently occurs on the head. Recent studies have revealed that an autoimmune abnormality is involved in the onset of alopecia areata, and alopecia areata is now recognized as a type of autoimmune disease. Normal hair follicle tissue and its surroundings are in a tolerant environment with little expression of MHC class I and II. In contrast, in alopecia areata lesions, the expression of MHC class I and II is enhanced, and immune tolerance of hair follicles is broken.
- activated lymphocytes mainly CD8-positive cytotoxic T cells
- accumulated around hair follicles recognize and attack self-antigens in hair roots in the tissue of hair loss caused by alopecia areata. and has been verified by various scientific studies (Non-Patent Document 1). It has been confirmed that these activated lymphocytes overproduce interferon ⁇ (IFN- ⁇ ), and this IFN- ⁇ is known to be a factor in the onset of alopecia areata.
- IFN- ⁇ interferon ⁇
- MHC class II expression of dendritic cells is also enhanced around the hair follicle of alopecia areata, and the enhanced expression of these MHC class I and II leads to the onset of alopecia areata.
- IFN- ⁇ is known as a cytokine that is a major cause of the onset of autoimmune diseases (Non-Patent Document 2), and is currently recognized as a potential target for autoimmune disease treatment.
- Alopecia areata is caused by the binding of IFN- ⁇ , which is overproduced in the hair follicle and its surrounding area, to cell membrane receptors, which transduces signals into the cells through the activation of Janus kinase, resulting in MHC class I and II. It is believed to be caused by overexpression.
- Non-Patent Document 3 Since hair growth is observed by inhibiting the activity of Janus kinase (Non-Patent Document 3), it is suggested that the treatment of alopecia areata, which suppresses the activity of IFN- ⁇ as a target molecule, may be useful. . Clinical studies in which anti-IFN- ⁇ antibodies were administered to patients with autoimmune diseases such as alopecia areata, rheumatoid arthritis, and multiple sclerosis for the purpose of neutralizing the activity of IFN- ⁇ showed improvement in symptoms. (Non-Patent Document 4).
- an anti-IFN- ⁇ antibody (1) is a biologic and therefore poses a risk of biological contamination; 3) Since it is a protein formulation, it has problems such as the need for a cold chain for storage and transportation.
- Janus kinase inhibitors include Tofacitinib (product name: Xeljanz (registered trademark)), Baricitinib (product name: Olumient (registered trademark)), Peficitinib (product name: Smyraf (registered trademark)), Upadacitinib (product name: Rinvok ( (Registered Trademark)) are applied to rheumatoid arthritis, which is an autoimmune disease, and are on the market. Since these Janus kinase inhibitors are low-molecular-weight compounds that can be produced by chemical synthesis, it is believed that they do not have the above-mentioned problems caused by being antibodies.
- Janus kinase there are multiple subtypes of Janus kinase, including not only IFN- ⁇ receptors, but also interleukin 2 (IL-2) receptors, interleukin 4 (IL-4) receptors, interleukin It is activated by binding to the intracellular domains of multiple cytokine receptors such as 7 (IL-7) receptor and interferon- ⁇ (IFN- ⁇ ) receptor, and transduces receptor signals.
- IL-2 interleukin 2
- IL-4 interleukin 4
- IFN- ⁇ interferon- ⁇
- Janus kinase inhibitors may inhibit not only IFN- ⁇ but also signaling of IL-2, IL-4, IL-7, IFN- ⁇ , etc. (Yvan Jamilloux, et. al., Autoimmunity Reviews, 2019, 18, 102390). This raises safety concerns in long-term administration and suggests the possibility of unexpected side effects.
- An object of the present invention is to provide a therapeutic drug for autoimmune diseases that can be stored at room temperature.
- the autoimmune disease therapeutic agent containing the oligonucleotide that selectively binds to IFN- ⁇ of the present invention as an active ingredient and the oligonucleotide adopt the following aspects.
- a first aspect of the present invention is an autoimmune autoimmune antibody containing, as an active ingredient, a DNA oligonucleotide that has a nucleotide sequence set forth in any one of SEQ ID NOs: 1 to 3 and selectively binds to interferon- ⁇ (IFN- ⁇ ).
- IFN- ⁇ interferon- ⁇
- the DNA oligonucleotides according to this aspect selectively bind to IFN- ⁇ to exert therapeutic effects on autoimmune diseases.
- the base sequence shown in SEQ ID NO: 2 is a sequence obtained by adding an oligonucleotide consisting of 9 natural bases to the 3' end of the base sequence shown in SEQ ID NO: 1.
- the base sequence shown in SEQ ID NO: 3 is a sequence obtained by substituting an arbitrary base for the 53rd base from the 5' end of the base sequence shown in SEQ ID NO: 2.
- the base X in the sequence of the DNA oligonucleotide having the base sequence shown in SEQ ID NO: 3 is an artificially produced base, and the artificially produced base is a low-molecular-weight It may be chemically modified with a compound.
- the small molecule compound in the first aspect is an anti-inflammatory compound selected from glucocorticoids, tacrolimus, sirolimus, cyclosporine, methotrexate, leflunomide, or erythromycin, azizuthromycin, kanamycin, ofloxacin, gatifloxa It may be an antibiotic selected from syn, tetracycline, vancomycin.
- the base X in the sequence of the DNA oligonucleotide having the base sequence shown in SEQ ID NO: 3 is an artificially produced base, and the artificially produced base is a middle molecule It may be chemically modified with a chemical compound, macromolecular compound, biopolymer, or biocompatible polymer.
- the middle molecular weight compound in the first aspect may have a molecular weight of about 1,000 to 20,000.
- the polymer compound in this aspect may have a molecular weight of about 20,000 to 400,000.
- the polymer compound in the first aspect may be any biocompatible polymer having a molecular weight of 20,000 or more.
- Middle-molecular-weight compounds or high-molecular-weight compounds in this embodiment include, but are not limited to, polyethylene glycol (PEG), bipolar polymers, oligosaccharides, fat-soluble polymers, peptides, oligonucleotides, antibodies, and the like.
- Antibodies belong to macromolecular compounds
- PEG, bipolar polymers, oligosaccharides, lipid-soluble polymers, peptides, oligonucleotides belong to medium-molecular compounds or macromolecular compounds depending on their molecular weights.
- the molecular weight of middle-molecular-weight compounds or high-molecular-weight compounds is represented by the average molecular weight defined by number average molecular weight (Mn) or weight average molecular weight (Mw).
- the autoimmune disease to be treated is the group consisting of alopecia areata, vitiligo vulgaris, psoriasis, scleroderma, dermatomyositis, atopic dermatitis, cutaneous lupus erythematosus, and IgA dermatitis. It may be an autoimmune skin disease selected from
- the autoimmune disease to be treated may be an autoimmune disease in the bladder selected from the group consisting of interstitial cystitis and bladder pain syndrome.
- the autoimmune disease in the eye is selected from the group consisting of uveitis, dry eye, keratitis sicca, episcleritis, and scleritis. It may be a disease.
- the autoimmune disease to be treated is multiple sclerosis, systemic lupus erythematosus, endometriosis, myocarditis, type I diabetes, thyroiditis, premature ovarian failure, Sjogren's syndrome, Raynaud's syndrome, rheumatoid arthritis, myasthenia gravis, Takayasu's arteritis, Addison's disease, Guillain-Barré syndrome, hypothyroidism, sarcoidosis, hemophagocytic lymphohistiocytosis, thrombotic thrombocytopenic purpura, autoimmune hepatitis It may be a systemic autoimmune disease selected from the group consisting of
- the autoimmune disease to be treated is selected from the group consisting of Crohn's disease, ulcerative colitis, autoimmune pancreatitis, biliary cholangitis, and autoimmune atrophic gastritis. It may also be an autoimmune disease of the digestive tract.
- a second aspect of the present invention is a DNA having a nucleotide sequence set forth in any one of SEQ ID NOs: 1 to 3 and having therapeutic effects on autoimmune diseases by selectively binding to interferon- ⁇ (IFN- ⁇ ).
- An oligonucleotide is provided.
- the DNA oligonucleotides according to this aspect selectively bind to IFN- ⁇ to exert therapeutic effects on autoimmune diseases.
- the base sequence shown in SEQ ID NO:2 is a sequence obtained by adding an oligonucleotide consisting of 9 natural bases to the 3' end of the base sequence shown in SEQ ID NO:1.
- the nucleotide sequence shown in SEQ ID NO: 3 is a sequence obtained by changing the 53rd base from the 5' end of the nucleotide sequence shown in SEQ ID NO: 2 to any base X, where X is any natural base or artificial is a base produced in According to this aspect, the artificially produced base in the sequence of the DNA oligonucleotide having the base sequence set forth in SEQ ID NO: 3 is chemically modified with the above-described low-molecular-weight compound, medium-molecular-weight compound, or high-molecular-weight compound.
- the autoimmune diseases to be treated by the drug for treating autoimmune diseases according to the second aspect include the above-exemplified autoimmune skin diseases, bladder autoimmune diseases, eye autoimmune diseases, systemic and autoimmune diseases of the digestive tract.
- the DNA oligonucleotides of the present invention having therapeutic effects on autoimmune diseases can selectively inhibit IFN- ⁇ by selectively binding to IFN- ⁇ .
- the DNA oligonucleotides of the present invention having therapeutic effects on autoimmune diseases do not require the use of serum or the like for their production, and therefore can be produced without the risk of biological contamination.
- the DNA oligonucleotides of the present invention having autoimmune disease therapeutic effects can be stored at room temperature, they are advantageous in terms of transportation and storage costs compared to conventional methods, and are convenient for patients to use. can improve sexuality.
- the DNA oligonucleotide of the present invention inhibits only the action of IFN- ⁇ even when administered for a long period of time, so that Janus kinase Unexpected side effects can be reduced compared to inhibitors and the like.
- the DNA oligonucleotides of the present invention when compared with anti-IFN- ⁇ antibodies, have lower antigenicity than antibodies, so they can be drugs that can be used for a long period of time.
- the DNA oligonucleotides of the present invention are safe from biological contamination and can be stored at room temperature.
- FIG. 2 is a diagram showing changes in the number of hairs on a skin graft tissue graft before and after administration of a DNA oligonucleotide according to an embodiment of the present invention, where the vertical axis indicates the change in the number of hairs per skin graft tissue graft.
- FIG. 2 shows suppression of MHC class I expression in the root sheath of the hair bulb by administration of a DNA oligonucleotide according to one embodiment of the present invention.
- FIG. 2 shows suppression of MHC class I expression in the outer root sheath by administration of a DNA oligonucleotide according to one embodiment of the present invention.
- FIG. 2 shows suppression of MHC class II expression in the connective tissue root sheath by DNA oligonucleotide administration according to one embodiment of the present invention.
- FIG. 2 shows suppression of MHC class II expression in the outer root sheath by administration of a DNA oligonucleotide according to one embodiment of the present invention.
- IFN- ⁇ is therefore recognized as a potential target for the treatment of autoimmune diseases.
- Emapalumab an anti-IFN- ⁇ antibody, was approved by the FDA in 2018 for hemophagocytic lymphohistiocytosis, which is an intractable autoimmune disease similar to the above-mentioned diseases, and was launched under the brand name Gamifant. ing.
- anti-IFN- ⁇ antibodies are subject to risks such as biological contamination due to being a biological preparation, antigenicity in long-term administration, and storage and transportation conditions due to being a protein preparation. I have an issue. Therefore, it is desired to solve these problems and create effective therapeutic drugs.
- a DNA aptamer is a single-stranded DNA oligonucleotide that forms a secondary structure or a tertiary structure by forming a complementary strand between complementary sequences in a DNA oligonucleotide molecule. It is a tightly binding ligand molecule. Binding of the DNA aptamer can inhibit, suppress or enhance the activity of the target molecule.
- a DNA aptamer has a high affinity and high target selectivity equivalent to that of an antibody, although its molecular weight is about 1/10 or less that of an antibody.
- IFN- ⁇ inhibitors using DNA aptamers can minimize the occurrence of side effects due to off-targets, and DNA aptamers can be produced by chemical synthesis, making them a suitable modality as a means of solving problems. It is considered that it can be.
- DNA aptamers (1) have a relatively small molecular weight and may be administered through transdermal formulations such as ointments and patches; (4) Since it is DNA, it is sufficiently stable at room temperature under nuclease-free neutral conditions. (5) It has almost no inhibitory activity on cytochrome P450, a drug-metabolizing enzyme. Therefore, it has advantages such as not affecting concomitant drugs, and its usefulness is expected. In addition, DNA aptamers do not cause the problem of the generation of antibodies against antibodies, which is one of the problems when long-term treatment using antibodies is required, and thus long-term administration is possible.
- the DNA oligonucleotide according to this embodiment can be used as a DNA aptamer.
- a method of treating diseases using DNA aptamers a method of treating autoimmune diseases by neutralizing IFN- ⁇ by administering the aptamer itself or a modified aptamer is envisioned.
- the DNA oligonucleotides listed in Table 1 are used as DNA aptamers.
- This embodiment includes using a DNA oligonucleotide having the nucleotide sequence shown in Table 1 as a therapeutic agent for autoimmune diseases.
- the sequence shown in SEQ ID NO: 2 in Table 1 is a sequence obtained by adding an oligonucleotide consisting of 9 natural bases to the 3' end of the sequence shown in SEQ ID NO: 1.
- the sequence shown by SEQ ID NO:3 in Table 1 is a sequence obtained by substituting an arbitrary base X for the 53rd base from the 5' end of the sequence shown by SEQ ID NO:2.
- X is any natural base, any unnatural base, or a modified base, or modified bases are low-molecular-weight compounds, peptides, oligonucleic acids, oligosaccharides, proteins, and other macromolecules used in living organisms. It represents a compound (biopolymer) or a substance bound with a biocompatible polymer.
- polymer compounds include polyethylene glycol (PEG) with a molecular weight of 20,000 or more and any biocompatible polymer with a molecular weight of 20,000 or more.
- a biocompatible polymer is a chemically synthesized product that is generally not used in vivo, and is safe as it does not cause inflammation or toxic reaction even when placed in the body.
- middle molecular weight compounds include peptides, oligonucleic acids, oligosaccharides, proteins, PEGs, and any biocompatible polymers with molecular weights greater than 1,000 and less than 20,000.
- low-molecular-weight compounds include antibiotics with a molecular weight of about 200-1000.
- Functional groups for modification include an azide group (--N 3 ), an amino group (--NH 2 ), a carboxyl group (--COOH) or an active ester thereof, an alkynyl group (--CC) or a cyclic structure containing an alkynyl structure.
- formyl group (-CHO), hydrazide group (-NH-NH 2 ), hydroxyl group (-OH), thiol group (-SH), cyano group (-CN), vinyl group (-CHCH 2 ), maleimide group are used. It is possible.
- natural base refers to adenine, guanosine, cytosine, or thymine.
- non-natural base refers to a base that is artificially synthesized and has properties similar to those of natural bases, and may also be referred to herein as “artificial base”.
- modified base refers to a base added with a side chain structure having one or more functional groups activated for modification, and is a type of "artificially produced base”. be.
- modifications include methylation, deamination, rearrangement of atomic positions, thiolation of oxygen at the phosphate site, and introduction of water-soluble or lipid-soluble substituents into the base moiety of natural bases. is mentioned. Specific examples include modified pyrimidines, modified purines, and other heterocyclic bases.
- Ds in the base sequences of SEQ ID NOS: 1 to 3 in Table 1 represents 7-(2-thienyl)imidazo[4,5-b]pyridine, which is an artificial base.
- the artificial base may be Ds itself or a base obtained by introducing a side chain into Ds.
- DNA aptamers having the sequences shown in SEQ ID NOS: 1, 2, and 3 in Table 1 are referred to as "aptamer 1,” “aptamer 2,” and “aptamer 1,” respectively. 3” (Aptamer 3).
- the DNA aptamer (aptamer 2) shown in Table 1 is injected intradermally into an autoimmune hair loss model of immunotolerant mice transplanted with human skin tissue fragments to suppress hair loss, In addition, it was confirmed that hair that had once fallen out can be regenerated (Example 4). Details will be described later.
- aptamer 2 or aptamer 3 Pathological analysis of the mechanism of expression of aptamer 2 or aptamer 3 activity in this model revealed that aptamer 2 or aptamer 3 almost completely suppressed the expression of MHC class I and II. Detailed results will be described later. In other words, aptamer 2 or aptamer 3 suppressed the production of MHC class I and II, which are the basis of autoimmunity, by inhibiting the activity of IFN- ⁇ , thereby improving autoimmunity. It is considered that the symptoms of alopecia were improved. This suggests that aptamer 2 or aptamer 3 is effective not only in alopecia areata but also in other autoimmune diseases (Vasiliki Matzaraki, et.
- DNA oligonucleotides having any of the sequences listed in Table 1 can be used as they are, or modified sites that do not affect the activity of these DNA aptamers can be used.
- modified DNA aptamers include PEG, peptides, oligonucleotides, and other middle-molecular-weight or high-molecular-weight compounds bound by chemical methods, DNA aptamers multimerized by chemical methods, DNA aptamers in which a part of the sequence is converted or modified are included.
- the modified portion is preferably a base portion. Artificial bases or modified bases can be modified using existing methods, and the 3' and 5' ends can also be modified.
- injection formulations can be formulated as vials containing lyophilized powder, vials containing aptamer solution, and prefilled syringes.
- the DNA aptamer of the present embodiment can be inhaled by inserting nanoparticles adsorbing or containing the DNA aptamer or a solution thereof, or powder obtained by granulating the DNA aptamer into an appropriate size with a granulating material into an inhalation device. It is possible to manufacture as a formulation for
- the DNA aptamer of this embodiment can be used as an eye drop by dissolving it as it is by utilizing its high water solubility.
- the DNA aptamer of this embodiment can be converted into fatty nanoparticles, biodegradable polymer nanoparticles such as PLGA (Polylactic-co-Glycolic Acid), gold nanoparticles, and the like. Encapsulated or adhered, dispersed or dissolved in physiological saline, physiological buffer, etc. can be used.
- biodegradable polymer nanoparticles such as PLGA (Polylactic-co-Glycolic Acid)
- gold nanoparticles and the like. Encapsulated or adhered, dispersed or dissolved in physiological saline, physiological buffer, etc. can be used.
- the DNA aptamer of this embodiment can be applied as transdermal topical agents such as solutions, ointments, creams, lotions, milky lotions, emulsions, gels, biodegradable microneedles, poultices, and the like.
- absorption enhancers include lower alcohols such as ethanol, polyhydric alcohols such as ethylene glycol, fatty acids, esters such as ethyl acetate, surfactants, and ionic liquids. etc. can be considered.
- lower alcohols such as ethanol
- polyhydric alcohols such as ethylene glycol
- fatty acids such as ethyl acetate
- surfactants such as ethyl acetate
- ionic liquids etc.
- the DNA aptamer of the present embodiment can also be used as an administration preparation using a device compatible with methods such as iontophoresis, electroporation, thermalporation, sonophoresis, microneedle array patch, needleless syringe, and micropump, which are physical percutaneous absorption enhancement methods. is possible.
- Example 1 Synthesis of DNA Aptamers Aptamers 1 and 2 were chemically synthesized by the method described in WO2013/073602 and WO2016/143700.
- Example 2 Synthesis Example of Aptamer 3 Using the method described in WO 2013/073602 and WO 2016/143700, Amino-Modifier C6-dT Amidite was added to position X in the sequence of SEQ ID NO: 3. introduced to synthesize aptamer 3. Other X-substituted compounds can be synthesized by using commercially available artificial bases or modified base amidites.
- Example 3 Synthesis of PEG-modified DNA aptamer Aptamer 3 (1 eq) having a primary amine side chain at the base moiety of X, prepared in Example 2, and commercially available NHS-PEG (40000) (1.5 eq) were mixed in a phosphate buffer of pH 7-8 and stirred at room temperature for 1 day. The reaction mixture was concentrated, and the resulting modified product was purified by reverse-phase HPLC to obtain PEG-modified aptamer 3. It was confirmed by SPR (Surface Plasmon Resonance) that the obtained PEG-modified aptamer 3 retained the ability to bind to IFN- ⁇ .
- SPR Surface Plasmon Resonance
- PEG-modified DNA aptamers are used to improve pharmacokinetics (PK)-pharmacodynamics (PD) profiles commonly used for oligonucleic acids including proteins, peptides, and aptamers for the purpose of improving pharmacokinetics. and many PEG-modified aptamers have been developed so far. It is known that when the PEG-modified aptamer retains its binding activity to the target protein, it exhibits activity equivalent to that of the aptamer before PEG modification in the body, and the toxicity due to PEG modification is almost non-existent ( C. Simone Fishburn, Journal of Pharmaceutical Sciences, 2008, 97, 10, 4167-4183; Katarina D. Kovacevic, et al., Advanced Drug Delivery Reviews, 2018-134, 36).
- Example 4 Confirmation of therapeutic effect using alopecia areata humanized model mouse Step 1 Preparation of humanized model mouse A. Gilhar, et. al. , Journal of Investigative Dermatology, 2013(133), 844-847, a humanized mouse model of alopecia areata induced by intradermal injection of human activated lymphocyte transplantation was prepared.
- Process 2 The produced humanized model mice were divided into 3 groups, and Vehicle (PBS), Dexamethasone+Minoxidil (Positive control), and Aptamer 2 were administered to each group.
- vehicle group 15 ⁇ L of PBS was administered to the grafted skin once every two days.
- aptamer-administered group 15 ⁇ L of aptamer solution in PBS was administered to the grafted skin once every two days, and the concentration of aptamer 2 solution was varied from 12 nM to 300 nM. Gradually increased over the course of the day.
- dexamethasone+minoxidil 2 mg of dexamethasone and 40 ⁇ L of 5% minoxidil were applied to the grafted skin once a day.
- FIG. 1 shows changes in the number of hairs on the skin graft before and after administration, and the vertical axis indicates the change in the number of hairs per skin graft.
- vehicle in Fig. 1
- hair loss further progressed during the period of administration of PBS, but in the positive control group ("Dexamethasone + Minoxidil” in Fig. 1) and the aptamer administration group ("Aptamer” in Fig. 1), Hair regrowth was observed while preventing further hair loss.
- MHC class I The results of MHC class I are shown in FIGS. 2A and 2B, and the results of MHC class II are shown in FIGS. 3A and 3B, respectively.
- the vertical axis represents the expression level of MHC class I (FIGS. 2A and 2B) or II (FIGS. 3A and 3B) in each vehicle group (FIGS. 2A, 2B, 3A, and "Vehicle" in FIG. 3B). It is shown as a relative value when the amount is set to 1.
- the hair follicle tissue recovered from the breakdown of immune tolerance, and a more fundamental therapeutic effect was obtained.
- the DNA aptamer according to this embodiment can suppress inflammatory reactions not only in autoimmune skin diseases but also in autoimmune diseases that occur in other tissues such as eyes and bladder by a similar mechanism. It shows that there is a
- the use of the therapeutic agent containing the DNA aptamer according to the present embodiment can prevent hair loss and further regenerate hair. Further, as a result of pathological analysis, it was confirmed that the administration of the DNA aptamer according to this embodiment can almost completely suppress the expression of MHC class I and II.
- Example 4 It is considered that the results in Example 4 above were caused by the strong inhibition of IFN- ⁇ activity by the DNA aptamer according to the present embodiment. Therefore, by using the DNA aptamer according to the present embodiment, it is possible to provide an unprecedentedly effective therapeutic drug and therapeutic method for autoimmune diseases such as alopecia areata.
- the DNA aptamer according to the present embodiment binds to IFN- ⁇ with high specificity.
- Janus kinase inhibitors Yvan Jamilloux, et. al., Autoimmunity Reviews, 2019, 18, 102390
- selective IFN- ⁇ activity The suppressing aptamer according to this embodiment can reduce the possibility of developing side effects.
- DNA aptamers generally have a low possibility of producing anti-DNA aptamer antibodies. Therefore, the DNA aptamer according to this embodiment can be administered over a long period of time in the treatment of autoimmune diseases.
- the DNA aptamer according to this embodiment can be produced completely by chemical synthesis. Therefore, it can be provided as a safe drug with stable quality and low risk of biological contamination.
- the DNA aptamer according to this embodiment can be manufactured at a lower cost than biologics. Further, in the case of biologics, low-temperature conditions are required for their preservation, whereas DNA aptamers are stable even at room temperature. Therefore, a cold chain is not necessarily required in transportation and storage of a formulation containing the DNA aptamer according to this embodiment.
- the DNA aptamer according to this embodiment By making the DNA aptamer according to this embodiment into a transdermal preparation, it is possible to provide a therapeutic drug that is easy to use, with no invasiveness in administration, and a low risk of side effects.
- the therapeutic agent containing the DNA aptamer according to this embodiment as an injection, it is possible to adapt to systemic autoimmune diseases. Also, when it is used as an injection, it can be made into a formulation that is easy for patients to use, such as a prefilled syringe that can be stored at room temperature.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Description
アプタマー1およびアプタマー2については、国際公開第2013/073602号および国際公開第2016/143700号に記載されている方法で化学合成した。
国際公開第2013/073602号および国際公開第2016/143700号に記載の方法を用い、配列番号3の配列のXの位置に、Amino-Modifier C6-dT Amiditeを導入して、アプタマー3を合成した。その他のX置換体に関しては、市販の人工塩基または修飾塩基のアミダイトを用いることにより合成できる。
実施例2で製造した、Xの塩基部分に1級アミン側鎖を有するアプタマー3(1eq)と、市販のNHS-PEG(40000)(1.5eq)とをpH7~8のリン酸バッファー中で混合し、室温下1日撹拌した。反応液を濃縮し、生成した修飾体を逆相HPLCで精製し、アプタマー3のPEG修飾体を得た。得られたアプタマー3のPEG修飾体については、SPR(Surface Plasmon Resonance)にてIFN-γとの結合能を保持していることを確認した。
工程1 ヒト化モデルマウスの作製
A.Gilhar, et.al.,Journal of Investigative Dermatology,2013(133),844-847に記載の方法に従い、ヒト活性化リンパ球の移植皮内注射により誘発される円形脱毛症のヒト化モデルマウスを作製した。
作製したヒト化モデルマウスを3群に分け、それぞれに、Vehicle(PBS)、Dexamethasone+Minoxidil (Positive control)、アプタマー2を投与した。Vehicle群に対しては、PBS15μLを2日に1回移植皮膚に投与した。アプタマー2を投与する群(以下、「アプタマー投与群」という)に対しては、アプタマーのPBS溶液15μLを2日に1回移植皮膚に投与し、アプタマー2の溶液の濃度を12nMから300nMまで143日間で徐々に増加させた。Dexamethasone+Minoxidilを投与する群に対しては、Dexamethasone2mgと5%Minoxidil40μLを、1日1回、移植皮膚に塗布した。
Claims (20)
- 配列番号1から3のいずれかに記載の塩基配列を有し、インターフェロンγ(IFN-γ)へ選択的に結合するDNAオリゴヌクレオチドを有効成分として含有する自己免疫性疾患治療薬。
- 配列番号3に示される塩基配列を有する前記DNAオリゴヌクレオチドの配列中の塩基Xが人工的に製造された塩基であり、前記人工的に製造された塩基が、低分子化合物で化学修飾されている、請求項1に記載の自己免疫性疾患治療薬。
- 前記低分子化合物が、グルココルチコイド、タクロリムス、シロリムス、サイクロスポリン、メトトレキサート、レフルノミドから選択される抗炎症化合物であるか、または、エリスロマイシン、アジズスロマイシン、カナマイシン、オフロキサシン、ガチフロキサシン、テトラサイクリン、バンコマイシンから選択される抗生物質である、請求項2に記載の自己免疫性疾患治療薬。
- 配列番号3に示される塩基配列を有する前記DNAオリゴヌクレオチドの配列中の塩基Xが人工的に製造された塩基であり、前記人工的に製造された塩基が中分子化合物、高分子化合物、生体高分子、または生体親和性のあるポリマーで化学修飾されている、請求項1に記載の自己免疫性疾患治療薬。
- 前記高分子化合物が、分子量20000以上のポリエチレングリコール(PEG)、または、分子量20000以上の生体親和性のある任意の高分子である、請求項4に記載の自己免疫性疾患治療薬。
- 配列番号1から3のいずれかに記載の塩基配列を有し、インターフェロンγ(IFN-γ)へ選択的に結合することで自己免疫性疾患治療効果を有するDNAオリゴヌクレオチド。
- 配列番号3に示される塩基配列中の塩基Xが人工的に製造された塩基であり、前記人工的に製造された塩基が、低分子化合物で化学修飾された、請求項6に記載の自己免疫性疾患治療効果を有するDNAオリゴヌクレオチド。
- 前記低分子化合物が、グルココルチコイド、タクロリムス、シロリムス、サイクロスポリン、メトトレキサート、レフルノミドから選択される抗炎症化合物であるか、または、エリスロマイシン、アジズスロマイシン、カナマイシン、オフロキサシン、ガチフロキサシン、テトラサイクリン、バンコマイシンから選択される抗生物質である、請求項7に記載の自己免疫性疾患治療効果を有するDNAオリゴヌクレオチド。
- 配列番号3に示される塩基配列中の塩基Xが人工的に製造された塩基であり、前記人工的に製造された塩基が、中分子化合物、高分子化合物、生体高分子、または生体親和性のあるポリマーで化学修飾された、請求項6に記載の自己免疫性疾患治療効果を有するDNAオリゴヌクレオチド。
- 前記人工的に製造された塩基を修飾する前記高分子化合物が、分子量20000以上のポリエチレングリコール(PEG)、または、分子量20000以上の生体親和性のある任意の高分子である、請求項9に記載の自己免疫性疾患治療効果を有するDNAオリゴヌクレオチド。
- 治療対象とする自己免疫性疾患が、円形脱毛症、尋常性白斑、乾癬、強皮症、皮膚筋炎、アトピー性皮膚炎、皮膚エリテマトーデス、IgA性皮膚炎からなる群から選択される自己免疫性皮膚疾患である、請求項1から5のいずれか1項に記載の自己免疫性疾患治療薬。
- 治療対象とする自己免疫性疾患が、間質性膀胱炎および膀胱痛症候群からなる群から選択される、膀胱における自己免疫性疾患である、請求項1から5のいずれか1項に記載の自己免疫性疾患治療薬。
- 治療対象とする自己免疫性疾患が、ぶどう膜炎、ドライアイ、乾性角膜炎、上強膜炎・強膜炎からなる群から選択される、目における自己免疫性疾患である、請求項1から5のいずれか1項に記載の自己免疫性疾患治療薬。
- 治療対象とする自己免疫性疾患が、多発性硬化症、全身性エリテマトーデス、子宮内膜症、心筋炎、I型糖尿病、甲状腺炎、早期卵巣不全、シェーングレン症候群、レイノー症候群、関節リウマチ、重症筋無力症、高安動脈炎、アジソン病、ギラン・バレー症候群、甲状腺機能低下症、サルコイドーシス、血球貪食性リンパ組織球症、血栓性血小板減少性紫斑病、自己免疫性肝炎からなる群から選択される、全身性の自己免疫性疾患である、請求項1から5のいずれか1項に記載の自己免疫性疾患治療薬。
- 治療対象とする自己免疫性疾患が、クローン病、潰瘍性大腸炎、自己免疫性膵炎、胆汁性胆道炎、自己免疫性萎縮性胃炎からなる群から選択される消化器の自己免疫性疾患である、請求項1から5のいずれか1項に記載の自己免疫性疾患治療薬。
- 治療対象とする自己免疫性疾患が、円形脱毛症、尋常性白斑、乾癬、強皮症、皮膚筋炎、アトピー性皮膚炎、皮膚エリテマトーデス、IgA性皮膚炎から選択される自己免疫性皮膚疾患である、請求項6から10のいずれか1項に記載のDNAオリゴヌクレオチドを有効成分として含有する自己免疫性疾患治療薬。
- 治療対象とする自己免疫性疾患が、間質性膀胱炎および膀胱痛症候群からなる群から選択される、膀胱における自己免疫性疾患である、請求項6から10のいずれか1項に記載のDNAオリゴヌクレオチドを有効成分として含有する自己免疫性疾患治療薬。
- 治療対象とする自己免疫性疾患が、ぶどう膜炎、ドライアイ、乾性角膜炎、上強膜炎、強膜炎からなる群から選択される、目における自己免疫性疾患である、請求項6から10のいずれか1項に記載のDNAオリゴヌクレオチドを有効成分として含有する自己免疫性疾患治療薬。
- 治療対象とする自己免疫性疾患が、多発性硬化症、全身性エリテマトーデス、子宮内膜症、心筋炎、I型糖尿病、甲状腺炎、早期卵巣不全、シェーングレン症候群、レイノー症候群、関節リウマチ、重症筋無力症、高安動脈炎、アジソン病、ギラン・バレー症候群、甲状腺機能低下症、サルコイドーシス、血球貪食性リンパ組織球症、血栓性血小板減少性紫斑病、自己免疫性肝炎からなる群から選択される、全身性の自己免疫性疾患である、請求項6から10のいずれか1項に記載のDNAオリゴヌクレオチドを有効成分として含有する自己免疫性疾患治療薬。
- 治療対象とする自己免疫性疾患が、クローン病、潰瘍性大腸炎、自己免疫性膵炎、胆汁性胆道炎、自己免疫性萎縮性胃炎からなる群から選択される消化器の自己免疫性疾患である、請求項6から10のいずれか1項に記載のDNAオリゴヌクレオチドを有効成分として含有する自己免疫性疾患治療薬。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022366465A AU2022366465A1 (en) | 2021-10-11 | 2022-10-07 | AUTOIMMUNE DISEASE THERAPEUTIC AGENT INCLUDING OLIGONUCLEOTIDE THAT SELECTIVELY BINDS TO IFN-γ, AND SAID OLIGONUCLEOTIDE |
CA3234569A CA3234569A1 (en) | 2021-10-11 | 2022-10-07 | Autoimmune disease therapeutic agent including oligonucleotide that selectively binds to ifn-y, and said oligonucleotide |
CN202280068586.8A CN118176301A (zh) | 2021-10-11 | 2022-10-07 | 含有与IFN-γ选择性结合的寡核苷酸的自身免疫性疾病治疗药物及该寡核苷酸 |
KR1020247011982A KR20240099173A (ko) | 2021-10-11 | 2022-10-07 | IFN-γ에 선택적으로 결합하는 올리고뉴클레오타이드를 함유하는 자가면역성 질환 치료제 및 그 올리고뉴클레오타이드 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021166794A JP7359457B2 (ja) | 2021-10-11 | 2021-10-11 | 自己免疫性疾患治療薬 |
JP2021-166794 | 2021-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023063242A1 true WO2023063242A1 (ja) | 2023-04-20 |
Family
ID=85987759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/037560 WO2023063242A1 (ja) | 2021-10-11 | 2022-10-07 | IFN-γへ選択的に結合するオリゴヌクレオチドを含有する自己免疫性疾患治療薬およびそのオリゴヌクレオチド |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP7359457B2 (ja) |
KR (1) | KR20240099173A (ja) |
CN (1) | CN118176301A (ja) |
AU (1) | AU2022366465A1 (ja) |
CA (1) | CA3234569A1 (ja) |
WO (1) | WO2023063242A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024029597A1 (ja) * | 2022-08-03 | 2024-02-08 | タグシクス・バイオ株式会社 | IFN-γへ選択的に結合するDNAオリゴヌクレオチドを含有するドライアイ治療薬 |
WO2024029560A1 (ja) * | 2022-08-03 | 2024-02-08 | タグシクス・バイオ株式会社 | IFN-γへ選択的に結合するDNAオリゴヌクレオチドを含有するハンナ型間質性膀胱炎治療薬 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008528569A (ja) * | 2005-01-27 | 2008-07-31 | ノビミューン エスアー | ヒト抗インターフェロンγ抗体およびその使用の方法 |
WO2013073602A1 (ja) | 2011-11-18 | 2013-05-23 | 独立行政法人理化学研究所 | 標的タンパク質に結合する核酸断片 |
WO2016143700A1 (ja) | 2015-03-06 | 2016-09-15 | タグシクス・バイオ株式会社 | Dnaアプタマーの安定化法 |
JP2017506243A (ja) * | 2014-02-21 | 2017-03-02 | プリンシピア バイオファーマ インコーポレイテッド | Btk阻害剤の塩および固体形態 |
JP2018506284A (ja) * | 2015-02-11 | 2018-03-08 | ディーキン・ユニバーシティー | EpCAMアプタマー及びそのコンジュゲート |
JP2020519562A (ja) * | 2017-05-05 | 2020-07-02 | エリクシロン イミュノセラピューティクス (ホンコン) リミテッド | 抗インターフェロンガンマ抗体およびその使用法 |
CN112813070A (zh) * | 2021-01-27 | 2021-05-18 | 复旦大学 | 结合河豚毒素的高亲和性核酸适配体及其获得方法和用途 |
JP2021100408A (ja) * | 2011-03-07 | 2021-07-08 | シャリテ−ウニヴェルジテーツメディツィン・ベルリンCharite−Universitaetsmedizin Berlin | 自己免疫疾患の治療及び/又は診断におけるアプタマーの使用 |
-
2021
- 2021-10-11 JP JP2021166794A patent/JP7359457B2/ja active Active
-
2022
- 2022-10-07 KR KR1020247011982A patent/KR20240099173A/ko unknown
- 2022-10-07 AU AU2022366465A patent/AU2022366465A1/en active Pending
- 2022-10-07 WO PCT/JP2022/037560 patent/WO2023063242A1/ja active Application Filing
- 2022-10-07 CA CA3234569A patent/CA3234569A1/en active Pending
- 2022-10-07 CN CN202280068586.8A patent/CN118176301A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008528569A (ja) * | 2005-01-27 | 2008-07-31 | ノビミューン エスアー | ヒト抗インターフェロンγ抗体およびその使用の方法 |
JP2021100408A (ja) * | 2011-03-07 | 2021-07-08 | シャリテ−ウニヴェルジテーツメディツィン・ベルリンCharite−Universitaetsmedizin Berlin | 自己免疫疾患の治療及び/又は診断におけるアプタマーの使用 |
WO2013073602A1 (ja) | 2011-11-18 | 2013-05-23 | 独立行政法人理化学研究所 | 標的タンパク質に結合する核酸断片 |
JP2017506243A (ja) * | 2014-02-21 | 2017-03-02 | プリンシピア バイオファーマ インコーポレイテッド | Btk阻害剤の塩および固体形態 |
JP2018506284A (ja) * | 2015-02-11 | 2018-03-08 | ディーキン・ユニバーシティー | EpCAMアプタマー及びそのコンジュゲート |
WO2016143700A1 (ja) | 2015-03-06 | 2016-09-15 | タグシクス・バイオ株式会社 | Dnaアプタマーの安定化法 |
JP2020519562A (ja) * | 2017-05-05 | 2020-07-02 | エリクシロン イミュノセラピューティクス (ホンコン) リミテッド | 抗インターフェロンガンマ抗体およびその使用法 |
CN112813070A (zh) * | 2021-01-27 | 2021-05-18 | 复旦大学 | 结合河豚毒素的高亲和性核酸适配体及其获得方法和用途 |
Non-Patent Citations (13)
Title |
---|
A. GILHAR, JOURNAL OF INVESTIGATIVE DERMATOLOGY, no. 133, 2013, pages 844 - 847 |
ANISEH SAMADI, JOURNAL OF DERMATOLOGICAL TREATMENT, vol. 28, no. 6, 2017, pages 476 - 483 |
B. SKURKOVICH.: "Ernst Schering Res", FOUND WORKSHOP, vol. 56, 2006, pages 1 - 27 |
C. SIMONE FISHBURN, JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 97, no. 10, 2008, pages 4167 - 4183 |
CARMEN GIANFRANI, JOURNAL OF AUTOIMMUNITY, no. 89, 2018, pages 1 - 10 |
GIULIO CAVALLI, PROC. NATL. ACAD. SCI. USA, vol. 113, no. 5, 2016, pages 1363 - 1368 |
JILLIAN F. RORK, CURR. OPIN. PEDIATR., vol. 28, no. 4, August 2016 (2016-08-01), pages 463 - 469 |
KATARINA D. KOVACEVIC, ADVANCED DRUG DELIVERY REVIEWS, vol. 134, 2018, pages 36 - 50 |
SIMON SKURKOVICH, EXPERT REV. CLIN. IMMUNOL., vol. 1, no. 1, 2005, pages 11 - 25 |
SUSAN A. ALALEHAN, SUR. J. IMMUNOL., vol. 45, 2015, pages 988 - 998 |
VASILIKI MATZARAKI, GENOME BIOLOGY, vol. 18, 2017, pages 76 |
VIKTOR STEIMLE, SCIENCE, vol. 265, no. 5168, 1994, pages 106 - 109 |
YVAN JAMILLOUX, AUTOIMMUNITY REVIEWS, vol. 18, 2019, pages 102390 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024029597A1 (ja) * | 2022-08-03 | 2024-02-08 | タグシクス・バイオ株式会社 | IFN-γへ選択的に結合するDNAオリゴヌクレオチドを含有するドライアイ治療薬 |
WO2024029560A1 (ja) * | 2022-08-03 | 2024-02-08 | タグシクス・バイオ株式会社 | IFN-γへ選択的に結合するDNAオリゴヌクレオチドを含有するハンナ型間質性膀胱炎治療薬 |
Also Published As
Publication number | Publication date |
---|---|
KR20240099173A (ko) | 2024-06-28 |
CN118176301A (zh) | 2024-06-11 |
JP2023057328A (ja) | 2023-04-21 |
JP7359457B2 (ja) | 2023-10-11 |
AU2022366465A1 (en) | 2024-05-02 |
CA3234569A1 (en) | 2023-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2023063242A1 (ja) | IFN-γへ選択的に結合するオリゴヌクレオチドを含有する自己免疫性疾患治療薬およびそのオリゴヌクレオチド | |
ES2871029T3 (es) | Dispositivos de liberación de fármacos recargables y procedimientos de uso de los mismos | |
JP2019519517A (ja) | 免疫調節ポリペプチドをコードするmRNAの組み合わせ及びその使用 | |
KR102064142B1 (ko) | 이중으로 유도화된 키토산 나노입자 및 이의 제조 방법과 생체 내 유전자 도입을 위하여 이를 이용하는 방법 | |
JP6680760B2 (ja) | アンタゴニストic pd−1アプタマー及びその癌治療関連用途への応用 | |
JP2022501336A (ja) | mRNA治療薬を使用したがんを治療するための方法及び組成物 | |
JP2004505009A (ja) | 新生物を処置するための組合せ | |
CN106793970A (zh) | 用于诊断及治疗的纳米载剂及其加工 | |
WO2019223293A1 (zh) | 骨架整合核苷类似物药物的功能性核酸及其衍生物和应用 | |
JP2019537432A (ja) | 標的化エフェクタータンパク質およびその使用 | |
US9050373B2 (en) | Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same | |
EP3389626A1 (en) | Sustained release cyclosporine-loaded microparticles | |
KR101336552B1 (ko) | 전립선암 특이적 siRNA 전달체 | |
WO2023192916A2 (en) | Rna comprising secretomes and methods of their use | |
JP6702938B2 (ja) | アンタゴニストic ctla−4アプタマー及びその免疫活性増強への応用 | |
US20210353767A1 (en) | Compositions and methods for drug delivery | |
JP7412576B2 (ja) | 腎がんの相乗的治療におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の適用 | |
WO2022109022A1 (en) | Rna-targeting splicing modifiers for treatment of mda5-associated conditions and diseases | |
WO2024029597A1 (ja) | IFN-γへ選択的に結合するDNAオリゴヌクレオチドを含有するドライアイ治療薬 | |
WO2024029560A1 (ja) | IFN-γへ選択的に結合するDNAオリゴヌクレオチドを含有するハンナ型間質性膀胱炎治療薬 | |
US20220401538A1 (en) | Therapeutic mrna vaccine for malignancies | |
Patil et al. | Insight of Engineered Nano-based Biologics Approaches used to Combat Autoimmune Disease using TNF-α & IL Inhibitors | |
WO2024124232A1 (en) | Nucleic acid based cancer vaccine and methods thereof | |
Shen | Development of Polymer-assisted Compaction of DNA Nanoparticles for Cancer Treatment. | |
WO2023245176A1 (en) | Targeted nanomedicine for treating fibrotic lung disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22880937 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022366465 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3234569 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022366465 Country of ref document: AU Date of ref document: 20221007 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022880937 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022880937 Country of ref document: EP Effective date: 20240513 |